HeartCare Medical-B (06609) Reports Unaudited 2021 Revenue of RMB 90.1 Million, a 517% Year-over-Year Increase

HeartCare-B(06609) Announced unaudited operational data for 2021, achieving revenue of approximately RMB 90.1 million, a year-on-year increase of 517%.

The announcement stated that the revenue growth was mainly attributed to: a full range of commercialized ischemic stroke thrombectomy devices (mainly including the company's Captor™ thrombectomy device and ExtraFlex™).

The significant increase in sales revenue of distal access catheters; and the additional revenue generated from the commercialization of intracranial artery stenosis treatment devices (including OpenVas intracranial balloon dilation catheters and ThruVas carotid balloon dilation catheters).